427 results on '"Zavascki, Alexandre P."'
Search Results
2. Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial
3. Substantial Diversity in Cocirculating Omicron Lineages in Hospital Setting, Porto Alegre, Brazil
4. A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
5. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients
6. Association between acute disease severity and one-year quality of life among post-hospitalisation COVID-19 patients: Coalition VII prospective cohort study
7. Melatonin for prevention of acute kidney injury in patients treated with intravenous polymyxin B: a double-blind, placebo-controlled randomized clinical trial
8. Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity
9. Clinical usefulness of tomographic standards for COVID-19 pneumonia diagnosis: Experience from a Brazilian reference center
10. Vancomycin and creatinine determination in dried blood spots: Analytical validation and clinical assessment
11. Clinical Use of Polymyxin B
12. Misassignment of patients in meta-analysis of polymyxin B
13. Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniaefrom bloodstream infections in hospitalized patients in Brazil
14. Increased frequency of blaNDM in a tertiary care hospital in southern Brazil
15. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection
16. A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol
17. KPC-producing Klebsiella pneumoniae bloodstream isolates from Brazilian hospitals: What (still) remains active?
18. Detection of Enterobacterales resistant to polymyxins using Rapid Polymyxins NP test
19. Low Doses of Colistimethate: Don't Rush In!
20. Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis
21. Dissemination of blaOXA-370 is mediated by IncX plasmids and the Tn6435 transposon
22. Which trial do we need? One or two antimicrobials with anti-pseudomonal activity for the empirical treatment of Ventilator-associated pneumonia due to Gram-negative bacteria
23. Population Pharmacokinetic Modeling of Free Plasma and Free Brain Concentrations of Ceftaroline in Healthy and Methicillin-Resistant Staphylococcus aureus-Infected Wistar Rats
24. Evaluation of clinical and microbiological factors related to mortality in patients with Gram-negative bacterial infections treated with ceftazidime–avibactam: A prospective multicentric cohort study
25. Effect of polymyxin B-containing regimens on renal function for the treatment of carbapenem-resistant Enterobacteriacea mediastinitis
26. Melatonin for prevention of acute kidney injury in patients treated with intravenous polymyxin B: a double-blind, placebo-controlled randomized clinical trial
27. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium
28. Heteroresistance to Carbapenems in New Delhi Metallo-β-Lactamase-1–Producing Isolates: A Challenge for Detection?
29. Double-, single- and none-carbapenem-containing regimens for the treatment of carbapenem-resistant Enterobacterales (CRE) bloodstream infections: a retrospective cohort
30. Reply to Pai
31. Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens
32. Characteristics of Enterobacteriaceae Isolates Coharboring Distinct Carbapenemase Genes
33. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia
34. Outbreak of Carbapenem-Resistant Providencia stuartii in an Intensive Care Unit
35. Polymyxin B Consumption and Incidence of Gram-Negative Bacteria Intrinsically Resistant to Polymyxins
36. Evaluation of Clinical Course of Gamma (P.1) Variant of Concern versus Lineages in Hospitalized Patients with COVID-19 in a Reference Center in Brazil
37. Reply to Kunin
38. Streptococcus pneumoniae appendicitis in an adult patient☆
39. Large hospital-wide outbreak of Paenibacillusspp pseudobacteremia associated with contaminated nonsterile gloves
40. Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients
41. Brazilʼs Family Health Strategy
42. High Endemic Rates of OXA-23-Producing Carbapenem-Resistant Acinetobacter baumannii Isolates Caused by the Persistence of Major Clones in Hospitals in a Brazilian City 5 Years After an Outbreak
43. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study
44. Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients
45. Performance of polymyxin B Etest in a setting of high prevalence of KPC-producing Klebsiella pneumoniae
46. Effect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study
47. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside
48. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
49. Getting Ready for the Covid-19 Pandemic: Experience of a Brazilian Hospital
50. Fungal Thyroiditis: An Overview
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.